NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Disclosed herein are novel fluorinated vinyl-N-propyl-pyrrolidine derivatives, the processes for their preparation, as well as the therapeutic uses thereof, in particular as anticancer agents via selective antagonism and degradation of estrogen receptors. The Estrogen Receptors (ER) belong to the steroid/nuclear receptor superfamily involved in the regulation of eukaryotic gene expression, cellular proliferation and differentiation in target tissues. ERs are in two forms: the estrogen receptor alpha (ERα) and the estrogen receptor beta (ERβ) respectively encoded by the ESR1 and the ESR2 genes. ERα and ERβ are ligand-activated transcription factors which are activated by the hormone estrogen (the most potent estrogen produced in the body is 17β-estradiol). In the absence of hormone, ERs are largely located in the cytosol of the cell. When the hormone estrogen binds to ERs, ERs migrate from the cytosol to the nucleus of the cell, form dimers and then bind to specific genomic sequences called Estrogen Response Elements (ERE). The DNA/ER complex interacts with co-regulators to modulate the transcription of target genes. ERα is mainly expressed in reproductive tissues such as uterus, ovary, breast, bone and white adipose tissue. Abnormal ERα signaling leads to development of a variety of diseases, such as cancers, metabolic and cardiovascular diseases, neurodegenerative diseases, inflammation diseases and osteoporosis. ERα is expressed in not more than 10% of normal breast epithelium but approximately 50-80% of breast tumors. Such breast tumors with high level of ERα are classified as ERα-positive breast tumors. The etiological role of estrogen in breast cancer is well established and modulation of ERα signaling remains the mainstay of breast cancer treatment for the majority ERα-positive breast tumors. Currently, several strategies for inhibiting the estrogen axis in breast cancer exist, including: 1- blocking estrogen synthesis by aromatase inhibitors that are used to treat early and advanced ERα-positive breast cancer patients; 2- antagonizing estrogen ligand binding to ERα by tamoxifen which is used to treat ERα-positive breast cancer patients in both pre- and post- menopausal setting; 3- antagonizing and downregulating ERα levels by fulvestrant, which is used to treat breast cancer in patients that have progressed despite endocrine therapies such as tamoxifen or aromatase inhibitors. Although these endocrine therapies have contributed enormously to reduction in breast cancer development, about more than one-third of ERα-positive patients display de novo resistance or develop resistance over time to such existing therapies. Several mechanisms have been described to explain resistance to such hormone therapies. For example, hypersensitivity of ERα to low estrogen level in treatment with aromatase inhibitors, the switch of tamoxifen effects from antagonist to agonist effects in tamoxifen treatments or multiple growth factor receptor signaling pathways. Acquired mutations in ERα occurring after initiation of hormone therapies may also play a role in treatment failure and cancer progression. Certain mutations in ERα, particularly those identified in the Ligand Binding Domain (LBD), result in the ability to bind to DNA in the absence of ligand and confer hormone independence in cells harboring such mutant receptors. Most of the endocrine therapy resistance mechanisms identified rely on ERα- dependent activity. One of the new strategies to counterforce such resistance is to shut down the ERα signaling by removing ERα from the tumor cells using Selective Estrogen Receptors Degraders (SERDs). Clinical and preclinical data showed that a significant number of the resistance pathways can be circumvented by the use of SERDs. There is still a need to provide SERDs with good degradation efficacy. Documents WO2017/140669 and WO2018/091153 disclose some substituted 6,7-dihydro-5H-benzo[7]annulene compounds and substituted N-(3-fluoropropyl)- pyrrolidine derivatives useful as SERDs. The inventors have now found novel compounds able to selectively antagonize and degrade the estrogen receptors (SERDs compounds), for use in cancer treatment. Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof:

wherein: - R1 and R2 independently represent a hydrogen atom or a deuterium atom; - R3 represents a hydrogen atom, a -COOH group or a -OH group; - R3’ and R3” independently represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom or a cyano group; - R4 and R4’ independently represent a hydrogen atom or a fluorine atom; - R5 represents a hydrogen atom, a fluorine atom or a (C ₁ -C ₃ )alkyl group; - R6 represents a group selected from: • a phenyl group, said phenyl group being optionally substituted by 1 to 3 substituents independently selected from a halogen atom; a (C ₁ -C ₆ )alkyl group optionally substituted with a cyano group or a -OH group; a (C ₁ -C ₆ )fluoroalkyl group; a (C ₃ -C ₆ )cycloalkyl group; a (C ₁ -C ₆ )alkoxy group; a (C ₁ -C ₆ )fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C ₁ -C ₄ )alkylthio group; a (C ₁ -C ₄ )fluoroalkylthio group; a (C ₁ -C ₄ )alkylsulfonyl group and a -OH group; • a fused phenyl group, selected from phenyl groups fused with a (C ₃ -C ₆ )cycloalkyl, said (C ₃ -C ₆ )cycloalkyl optionally comprises an unsaturation, and wherein the fused phenyl group is optionally substituted with 1 to 3 substituents independently selected from a (C ₁ -C ₃ )alkyl group, a hydroxy group, a halogen atom, a (C ₁ -C ₆ )fluoroalkyl group and a (C ₁ -C ₃ )alkoxy group; • a bicyclic group comprising 5 to 12 carbon atoms, optionally comprising 1 to 2 unsaturations; optionally substituted with 1 to 4 substituents independently selected from: a fluorine atom, a -OH group, a (C ₁ -C ₃ )alkyl group, a (C ₁ -C ₃ )fluoroalkyl group, a (C ₁ -C ₃ )alkoxy group, a (C ₁ -C ₃ )fluoroalkoxy group and an oxo group; • a heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, said heteroaryl group being optionally substituted with 1 to 3 substituents independently selected from a halogen atom, a (C ₁ -C ₆ )alkyl group, a (C ₁ -C ₆ )fluoroalkyl group, a (C ₁ -C ₆ )alkoxy group, a (C ₁ -C ₆ )fluoroalkoxy group, a cyano group, a carbamoyl group and a -OH group; • a cycloalkyl group comprising 3 to 7 carbon atoms, said cycloalkyl group being saturated or partially saturated and being optionally substituted with 1 to 4 substituents independently selected from: o a fluorine atom, a -OH group, a (C ₁ -C ₃ )alkyl group, a (C ₁ -C ₃ )fluoroalkyl group, a (C ₁ -C ₃ )alkoxy group, a (C ₁ -C ₃ )fluoroalkoxy group, an oxo group, o a (C ₃ -C ₆ )cycloalkyl group and a phenyl group, said (C ₃ -C ₆ )cycloalkyl or phenyl groups being optionally substituted with one or two halogen atom(s) or (C ₁ -C ₃ )alkyl group(s); • a (C ₃ -C ₆ )cycloalkyl(C ₁ -C ₃ )alkyl group, optionally substituted on the cycloalkyl with 1 to 4 substituents independently selected from: a fluorine atom, a -OH group, a (C ₁ -C ₄ )alkyl group, a (C ₁ -C ₃ )fluoroalkyl group, a (C ₁ -C ₃ )fluoroalkoxy group and an oxo group; • a 4 to 7 membered-heterocycloalkyl group comprising 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, such as a tetrahydropyranyl group, said heterocycloalkyl group being saturated or partially saturated and being optionally substituted with 1 to 3 substituents independently selected from: a fluorine atom, a (C ₁ -C ₃ )alkyl group, a (C ₁ -C ₃ )fluoroalkyl group, a (C ₁ -C ₃ )fluoroalkoxy group, an oxo group, a (C ₁ -C ₃ )alkoxy group, and a -OH group; • a (C ₁ -C ₆ )alkyl group, such as an isobutyl group, a methyl group or an ethyl group, said alkyl group being optionally substituted with 1 to 4 substituents independently selected from: a fluorine atom, a (C ₁ -C ₃ )alkoxy group, a (C ₁ -C ₃ )fluoroalkoxy group and a -OH group; and • a phenyl(C ₁ -C ₂ )alkyl group, said phenyl group being optionally substituted with 1 to 3 substituents independently selected from a halogen atom; a (C ₁ -C ₃ )alkyl group; a (C ₁ -C ₃ )fluoroalkyl group; a (C ₁ -C ₃ )alkoxy group; a (C ₁ -C ₃ )fluoroalkoxy group; a cyano group; and a -OH group; - X represents -CH ₂ -, -O- or -S-; - Y represents -CH=, -N= or -CR”=, wherein R” represents a (C ₁ -C ₃ )alkyl group, a halogen atom, such as a fluorine or a chlorine atom, a cyano group, or a (C ₁ -C ₃ )fluoroalkyl group, such as trifluoromethyl; - R7 independently represents a (C ₁ -C ₃ )alkyl group such as methyl, a halogen atom such as a fluorine atom, a cyano group, or a (C ₁ -C ₃ )fluoroalkyl group such as trifluoromethyl; - R8 represents a hydrogen atom or a fluorine atom; - R9 represents a hydrogen atom, a (C ₁ -C ₃ )alkyl group or a cyclopropyl; - n is 0, 1 or 2; and - m is 0 or 1. The compounds of formula (I) can contain one or more asymmetric carbon atoms. They may therefore exist in the form of enantiomers. The compounds of formula (I) may be present as well under tautomer forms. The compounds of formula (I) may exist in the form of bases, acids, zwitterion or of addition salts with acids or bases. Hence, herein are provided compounds of formula (I) or pharmaceutically acceptable salts thereof. These salts may be prepared with pharmaceutically acceptable acids or bases, although the salts of other acids or bases useful, for example, for purifying or isolating the compounds of formula (I) are also provided. Among suitable salts of the compounds of formula (I), hydrochloride may be cited As used herein, the terms below have the following definitions unless otherwise mentioned throughout the instant specification: - a halogen atom: a fluorine, a chlorine, a bromine or an iodine atom, and in particular a fluorine and a chlorine atom; - an oxo: a “=O” group; - an alkyl group: a linear or branched saturated hydrocarbon-based aliphatic group comprising, unless otherwise mentioned, from 1 to 6 carbon atoms (noted “(C ₁ -C ₆ )alkyl”). By way of examples, mention may be made of, but not limited to: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl and isohexyl groups, and the like; - a cycloalkyl group: a monocyclic alkyl group comprising, unless otherwise mentioned, from 3 to 7 carbon atoms, saturated or partially unsaturated and unsubstituted or substituted. By way of examples, mention may be made of, but not limited to: cyclopropyl, cyclobutyl, cyclopentyl, cyclobutenyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl and cycloheptenyl groups and the like, in particular a cyclopentyl, a cyclohexyl or a cyclohexenyl; - a cycloalkylalkyl group: an alkyl group substituted with a cyclic alkyl group as defined above. Mention may be made of, but not limited to: cyclobutylmethyl; - a heterocycloalkyl group: a 4 to 7-membered cycloalkyl group, saturated or partially unsaturated, comprising 1 to 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, in particular being oxygen or nitrogen. By way of examples, mention may be made of, but not limited to: morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, aziridinyl, oxanyl, oxetanyl, tetrahydropyranyl, morpholinyl, tetrahydrofuranyl, oxepanyl, diazepanyl, dioxanyl, tetrahydropyranyl and tetrahydrothiopyranyl. The heterocycloalkyl is advantageously tetrahydropyranyl. - a fluoroalkyl group: an alkyl group as previously defined where the alkyl group is substituted with at least one fluorine atom. In other terms, at least one hydrogen atom of the alkyl group is replaced by a fluorine atom. By way of example, mention may be made of -CH ₂ F, -CHF ₂ , -CH ₂ CHF ₂ , -CH ₂ CH ₂ F and the like. When all the hydrogen atoms belonging to the alkyl group are replaced by fluorine atoms, the fluoroalkyl group can be named perfluoroalkyl group. By way of example, mention may be made of trifluoromethyl group or trifluoroethyl group and the like, and in particular trifluoromethyl group; - an alkoxy group: an -O-alkyl group where the alkyl group is as previously defined. By way of examples, mention may be made of, but not limited to: methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, isobutoxy, pentoxy or hexoxy groups, and the like; - a fluoroalkoxy group: an -O-alkyl group where the alkyl group is as previously defined and where the alkyl group is substituted with at least one fluorine atom. In other terms, at least one hydrogen atom of the alkyl group is replaced by a fluorine atom. By way of example, mention may be made of -OCH ₂ F, -OCHF ₂ , -OCH ₂ CH ₂ F and the like. When all the hydrogen atoms belonging to the alkyl group are replaced by fluorine atoms, the fluoroalkoxy group can be named perfluoroalkoxy group. By way of example, mention may be made of trifluoromethoxy group and the like; - a (C ₁ -C ₄ )alkylthio group also named (C ₁ -C ₄ )alkylsulfanyl: a -S-alkyl group where the alkyl group is as previously defined. By way of examples, mention may be made of, but not limited to: methylthio, ethylthio, propylthio, isopropylthio, linear, secondary or tertiary butylthio, isobutylthio, and the like; - a (C ₁ -C ₄ )alkylsulfonyl group: a -SO ₂ -alkyl group where the alkyl group is as previously defined. By way of examples, mention may be made of, but not limited to: -SO ₂ CH ₃ , -SO ₂ CH ₂ CH ₃ and the like; - a (C ₁ -C ₄ )fluoroalkylthio group also named a (C ₁ -C ₄ )fluoroalkylsulfanyl group: a -S- fluoroalkyl group where the fluoroalkyl group is as previously defined. By way of examples, mention may be made of, but not limited to: fluoromethylthio, difluoromethylthio, trifluoromethylthio and the like; - a fused phenyl: a bicyclic radical comprising from 7 to 10 carbon atoms and that contains a phenyl moiety. Said phenyl moiety may be fused to a (C ₃ -C ₆ )cycloalkyl group, i.e. the phenyl moiety may share a bond with said (C ₃ -C ₆ )cycloalkyl group. The fused phenyl group may be bound to the rest of the molecule by its phenyl moiety. It may be substituted. Examples are, but not limited to, indanyl, bicyclo[4.2.0]octa-1(6),2,4-trienyl, tetrahydronaphthalenyl and the like; - a heteroaryl group: a 5 to 10-membered cyclic aromatic group containing between 2 and 9 carbon atoms and containing between 1 and 3 heteroatoms, such as nitrogen, oxygen or sulfur. Such nitrogen atom may be substituted with an oxygen atom in order to form a –N- O bond. Such -N-O bond can be in a form of a N-oxide (-N ⁺ -O-). Said heteroaryl group may be monocyclic or bicyclic. By way of examples of heteroaryl groups, mention may be made of, but not limited to: thiophene, furan, thiadiazole, thiazole, imidazole, pyridazine, triazine, pyrazine, oxadiazole, pyrazole, isothiazole, oxazole, isoxazole, pyridine, pyrimidine, benzotriazole, benzoxazole, pyrrolo[2,3-b]pyridine, benzimidazole, benzoxadiazole, benzothiazole, benzothiadiazole, benzofuran, indole, isoquinoline, indazole, benzisoxazole, benzisothiazole, pyridone groups and the like. The heteroaryl is advantageously pyridine, pyrrole, imidazole, pyrazine, furane, thiazole, pyrazole, thiadiazole, pyridazine, pyridone and pyrimidine, and more particularly pyridine; - a bicyclic group, generally comprising 5 to 12 carbon atoms, is a hydrocarbon group selected from groups comprising two rings connected through: • a single common atom: a “spirobicyclic ring”. Such spiro bicyclic alkyl generally comprises 5 to 11 carbon atoms referring to a “spiro(C ₅ -C ₁₁ )bicyclic ring”. The rings may be saturated or partially unsaturated. Such spirobicyclic ring may be unsubstituted or substituted, in particular by at least one (C ₁ -C ₃ )alkyl group such as methyl or a fluorine. By way of examples of spiro(C ₅ -C ₁₁ )bicyclic ring as for the definition of R6, mention may be made of, but not limited to: spiro[2.3]hexane, spiro[3.3]heptane, spiro[3.3]heptene, spiro[2.5]octane and 7-azaspiro[3.5]nonane. The spiro(C ₅ -C ₁₁ )bicyclic ring is advantageously spiro[2.3]hexane, spiro[3.3]heptane or spiro[3.3]heptene still for the R6 group; • two common atoms: In that case the bicyclic group comprises 7 to 12 carbon atoms and optionally comprises 1 to 2 unsaturations. By way of examples of such bicyclic groups, mention may be made of, but not limited to: cis-1,3a,4,5,6,6a-hexahydropentalenyl group, bicyclo[3.1.0]hexan-1-yl, bicyclo[4.1.0]heptanyl and octahydropentalenyl, • three or more common atoms: In that case the bicyclic group comprises 6 to 10 carbon atoms, such bicyclic group may be referred to as a “bridged (C6-C10)cycloalkyl” group, the rings share three or more atoms and the bridge contains at least one atom, for example 1, 2 or 3 atoms and preferentially 1 atom. By way of examples of such bridged cycloalkyl groups, mention may be made of, but not limited to bicyclo[3.2.1]octan-3-yl and bicyclo[2.2.1]heptan-2-yl. - a zwitterion means: a globally neutral molecule with a positive and a negative electrical charge and having an acidic group and a basic group. In another embodiment, in the compounds of formula (I) as defined above, R1 and R2 are a hydrogen atom. In another embodiment, in the compounds of formula (I) as defined above, R3 is a -COOH group. In another embodiment, in the compounds of formula (I) as defined above, R3’ and R3” both represent a hydrogen atom. In another embodiment, in the compounds of formula (I) as defined above, X represents - -CH ₂ -. In another embodiment, in the compounds of formula (I) as defined above, R4 and R4’ both represent a hydrogen atom or one of R4 and R4’ represents a hydrogen atom and the other a fluorine atom. In another embodiment, in the compounds of formula (I) as defined above, R5 represents a hydrogen atom. In another embodiment, in the compounds of formula (I) as defined above, R6 represents a phenyl group, said phenyl group being optionally substituted with 1 to 3 substituents independently selected from a halogen atom; a (C ₁ -C ₆ )alkyl group and a (C ₁ -C ₆ )fluoroalkyl group, more particularly selected from a chlorine atom, a fluorine atom, a methyl group and a trifluoromethyl group. In such embodiment, in particular, at least one of the substituents of said phenyl group comprises a halogen atom. In another embodiment, in the compounds of formula (I) as defined above, n is 0 or 1 and R7 is a fluorine atom. In another embodiment, in the compounds of formula (I) as defined above, n is 0. In another embodiment, in the compounds of formula (I) as defined above, Y represents -CH=. In another embodiment, in the compounds of formula (I) as defined above, m is 1. In another embodiment, in the compounds of formula (I) as defined above, m is 0. In another embodiment, in the compounds of formula (I) as defined above, R3 is a -COOH group and R6 is a phenyl group comprising one, two or three substitutions, more particularly two substitutions, independently selected from a chlorine atom, a fluorine atom, a trifluoromethyl group and a methyl group, at least one of the substitutions comprising a halogen atom. In such embodiment, R3’ and R3” are in particular hydrogen atoms. Still in such embodiment, R1, R2, R5, R8 and R9 are hydrogen atoms. In such embodiment, both R4 and R4’ are hydrogen atoms or one of R4 and R4’ is a hydrogen atom and the other is a fluorine atom. Still in such embodiment, Y is a -CH= group, m is equal to 1 and n is equal to 0. Still in such embodiment, X is a -CH ₂ - group. Among the compounds of formula (I) described herein, mention may be made in particular of the following compounds or a pharmaceutically acceptable salt thereof, in particular hydrochloride salt thereof: - (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrol idin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid hydrochloride (1), - (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)p yrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (2), - (Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]oxepine-8-carboxyl ic acid hydrochloride (3), - Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrro lidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (4), - (Z)-8-(2,4-difluorophenyl)-9-(4-((1-(3,3-difluoropropyl)pyrr olidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid hydrochloride (5), - (Z)-8-(4-fluoro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyr rolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (6), - (Z)-3-(4-(8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulen- 9-yl)benzylidene)- 1-(3-fluoropropyl)pyrrolidine (7), - (Z)-8-(4-fluoro-2-(trifluoromethyl)phenyl)-9-(4-((1-(3-fluor opropyl)pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (8), - (Z)-8-(2,4-difluorophenyl)-9-(4-((1-(3,3-fluoropropyl)pyrrol idin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic (9), - (Z)-8-(3-chloro-2-methylphenyl)-9-(4-((1-(3-fluoropropyl)pyr rolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (10), - (Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phe nyl)-8-(3-methyl-2- (trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-c arboxylic acid (11), - (Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl )phenyl)-8-(3-methyl- 2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylic acid (12), - (Z)-8-(3-chloro-2-methylphenyl)-9-(4-((1-(3,3-difluoropropyl )pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (13), - (Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phe nyl)-8-(2-methyl-3- (trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-c arboxylic acid (14), - (Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl )phenyl)-8-(4-fluoro- 2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (15), - (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-ol hydrochloride (16), - (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-difluoropropyl)pyrrol idin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-ol hydrochloride (17), - (Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl )phenyl)-8-(4-fluoro- 2-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylic acid (18), - (Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl )phenyl)-8-(2-methyl- 3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylic acid (19), - (Z)-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl )phenyl)-8-(4-fluoro- 2,6-dimethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carbo xylic acid (20), - (Z)-8-(4-fluoro-2,6-dimethylphenyl)-9-(4-((1-(3-fluoropropyl )pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (21), - (Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phe nyl)-8-(2- (trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-c arboxylic acid (22), - (Z)-8-(2,4-dichlorophenyl)-9-(3-fluoro-4-((1-(3-fluoropropyl )pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (23), - (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride (24), - (Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phe nyl)-8-(3- (trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-c arboxylic acid (25), - (Z)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phe nyl)-8-(4- (trifluoromethyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-c arboxylic acid (26), - (Z)-8-(3-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3 - ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (27), - (Z)-8-(4-chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3 - ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (28), - (Z)-8-(4-fluoro-2,5-dimethylphenyl)-9-(4-((1-(3-fluoropropyl )pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid (29), - (Z)-4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-ol (30). Another embodiment is a compound selected from the above list, or a pharmaceutically acceptable salt thereof, for use in therapy, especially as an inhibitor and degrader of estrogen receptors. Another embodiment is a compound selected from the above list, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, especially breast cancer. Another embodiment is a method of inhibiting and degrading estrogen receptors, comprising administering to a subject in need thereof, in particular a human, a therapeutically effective amount of a compound selected from the above list, or a pharmaceutically acceptable salt thereof. Another embodiment is a method of treating ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation, comprising administering to a subject in need thereof, in particular a human, a therapeutically effective amount of a compound selected from the above list, or a pharmaceutically acceptable salt thereof. Another embodiment is a method of treating cancer, comprising administering to a subject in need thereof, in particular a human, a therapeutically effective amount of a compound selected from the above list, or a pharmaceutically acceptable salt thereof. Another embodiment is a pharmaceutical composition comprising as active principle an effective dose of a compound selected from the above list, or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient. The compounds of the formula (I) can be prepared by the following processes. The compounds of the formula (I) and other related compounds having different substituents are synthesized using techniques and materials described below or otherwise known by the skilled person in the art. In addition, solvents, temperatures and other reaction conditions presented below may vary as deemed appropriate to the skilled person in the art. General below methods for the preparation of compounds of formula (I) optionally modified by the use of appropriate reagents and conditions for the introduction of the various moieties found in the formula (I) as described below. The following abbreviations and empirical formulae are used: MeCN Acetonitrile NH4Cl Ammonium chloride CO Carbon monoxide CO ₂ Carbon dioxide Cs2CO3 Cesium carbonate DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene DCM Dichloromethane Et2O Diethyl ether DIEA Diisopropylethylamine DMF N,N-dimethylformamide DMAP Dimethylaminopyridine DMSO Dimethyl sulfoxide BOC ₂ O di-ter-butyldicarbonate EtOH Ethanol EtOAc Ethyl acetate HCl Hydrochloric acid LiHMDS Lithium bis(trimethylsilyl)amide LiOH Lithium hydroxide MeOH Methanol MgSO ₄ Magnesium sulfate MTBE Methyl tert-butyl ether MeTHF 2-Methyltetrahydrofuran n-BuLi n-Butyllithium KOAc Potassium acetate KHMDS Potassium bis(trimethylsilyl)amide K ₂ CO ₃ Potassium carbonate KOH Potassium hydroxide NaBH ₄ Sodium borohydride NaHCO ₃ Sodium bicarbonate NaH Sodium hydride NaOH Sodium hydroxide Na ₂ SO ₄ Sodium sulfate SCX Strong cation exchange Pd(dppf)Cl ₂ [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II ) Pd(PPh ₃ ) ₂ Cl ₂ bis (triphenylphosphine) palladium(II) dichloride Pd ₂ (dba) ₃ tris(dibenzylideneacetone)dipalladium(0) PhOK Potassium phenolate SFC Supercritical Fluid Chromatography TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran PPh ₃ Triphenylphosphine RT Room temperature XANTPHOS (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane).

SCHEME 1a – Part-1: Preparation of compounds of the formula (I) – General process SCHEME 1a – Part-2 According to SCHEME 1a – Part-1 and Part-2, in which R3a is a hydrogen atom or a carboxylic ester such as COOMe, COOEt, or protected OH such as O-pivaloyl, R6 is a phenyl group or a heteroaryl group; and R1, R2, R3, R3’, R3’’, R4, R4’, R5, R7, R8, R9 X, m, n and Y are as defined above, compound 1A can be converted in STEP 1 to compound 1B by treatment with aryl or heteroaryl bromide or iodide in the presence of a palladium catalyst, for example tris(dibenzylideneacetone)dipalladium(0) Pd ₂ (dba) ₃ , and a phosphine such as (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane) (XANTPHOS) in solution in toluene or xylene by heating up to reflux of solvent, in presence of a base such as K ₂ CO ₃ or Cs ₂ CO ₃ . Alternative way to prepare compound 1B, wherein R6 can be any of the groups defined above for R6 in formula (I), is described in SCHEME 1e below. Compound 1B can be converted in STEP 2 to compound 1C by treatment with N,N-bis(trifluoromethylsulfonyl)aniline in the presence of a base such as DBU or NaH, or KHMDS at -50°C, in a solvent such as MeTHF. Compound 1C can be converted in STEP 4 to compound 1E by treatment for example with bis(pinacolato)diboron, and with a palladium catalyst, for example bis (triphenylphosphine) palladium(II) dichloride Pd(PPh ₃ ) ₂ Cl ₂ , and a phosphine, such as triphenylphosphine, in solution in toluene by heating up to reflux of solvent, in presence of a base such as KOPh. Compound 1K can be prepared in a Suzuki coupling reaction either between compounds 1C and 1D in STEP 3 or between compounds 1E and 1F in STEP 5 using for example [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (Pd(dppf)Cl ₂ ), complex with DCM, as catalyst, in a mixture of dioxane and water and in the presence of a base, for example cesium carbonate (Cs ₂ CO ₃ ), by heating up to reflux of solvent. Alternatively, compound 1E can be converted in STEP 6 to compound 1H in a Suzuki coupling reaction with compound 1G using for example [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl ₂ ), complex with DCM, as catalyst, in a mixture of dioxane and water and in the presence of a base, for example cesium carbonate (Cs ₂ CO ₃ ), by heating up to reflux of solvent. Compound 1H can be converted in STEP 7 to compound 1I by treatment with TFA in solution in DCM or HCl in solution in dioxane. Compound 1I can be converted in STEP 8 to compound 1K by treatment with compound 1J, wherein W is Br, I or OSO ₂ R with R = CH ₃ , PhMe, CF ₃ or CF ₂ CF ₂ CF ₂ CF ₃ , in presence of a base such as potassium carbonate in DMF at 70°C or in presence of sodium hydroxide or potassium hydroxide in THF at room temperature or in presence of aqueous sodium hydroxide in DCM at room temperature. When R3a is COOMe, COOEt, or a protected OH such as O-pivaloyl, compound 1K can be deprotected into compound I in STEP 9 by treating with an aqueous solution of sodium hydroxide (NaOH) or lithium hydroxide (LiOH), in MeOH. When R3 is COOH, extraction of compound could give the sodium salt of compound I. The acidification with an aqueous solution of HCl 2N to pH 6-7 could give the neutral form. The acidification with an aqueous solution of HCl 2N to pH 1-2 could give the hydrochloride salt. The purification using HPLC could give the formate or trifluoroacetate salt.

SCHEME 1b – Part-1 and Part-2: Alternative processes to prepare compounds of the Formula (I) – General process SCHEME 1b – Part-1:

SCHEME 1b – Part-2: According to SCHEME 1b – Part-1 and – Part-2, in which R3a is a hydrogen atom, carboxylic ester such as COOMe, COOEt, or protected OH such as O-pivaloyl, R1, R2, R3, R3’, R3’’, R4, R4’, R6, R7, R8, R9, X, n, m and Y are as defined above and R5 is a hydrogen atom, compound 1L can be converted in STEP 1 to compound 1N in a Suzuki coupling reaction with compound 1M using for example [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (Pd(dppf)Cl ₂ ), complex with DCM, as catalyst, in a mixture of dioxane and water and in the presence of a base, for example Cs ₂ CO ₃ , by heating up to reflux of solvent. Compound 1N can be converted in STEP 2 to compound 1O by treatment for example with pyridinium tribromide in DCM or THF at room temperature. Compound 1O can be converted in STEP 3 to compound 1P by treatment with sulfuric acid in solution in water. Compound 1P can be converted in STEP 4 to compound 1Q by treatment for example with bis(pinacolato)diboron, and with a palladium catalyst, for example bis (triphenylphosphine) palladium(II) dichloride Pd(PPh ₃ ) ₂ Cl ₂ , and a phosphine such as triphenylphosphine in solution in toluene by heating up to reflux of solvent in presence of a base such as KOPh or AcOK. Compound 1K can be prepared in a Suzuki coupling reaction either between compounds 1P and R6B(OR’)2 or R6BF3K, wherein -B(OR’)2 is a boronic acid or a pinacolate ester and R6 is as defined above, in STEP 5 or between compounds 1Q and R6Br or R6I in STEP 6 using for example [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (Pd(dppf)Cl ₂ ), complex with DCM, as catalyst, in a mixture of dioxane and water and in the presence of a base, for example cesium carbonate (Cs ₂ CO ₃ ), by heating up to reflux of solvent. Alternative way to prepare compound 1K, wherein R5 can be any of the groups defined above for R5 in formula (I), is described in SCHEME 1f below. Compound 1K can be converted in STEP 7 to compound of formula (I) in presence of a source of hydroxide ions such as NaOH or LiOH in solution in MeOH. Compound 1P can be converted in STEP 8 to compound 1Pa in the presence of a source of hydroxide ions such as NaOH or LiOH in solution in MeOH. This compound 1Pa can be converted in STEP 9 to compound I through Suzuki conditions using a suitable boronic reagent R6B(OR’)2 or R6BF ₃ K, wherein -B(OR’)2 is a boronic acid or a pinacolate ester and R6 is as above defined, using for example Pd(dppf)Cl ₂ , complex with DCM, as catalyst, in a mixture of dioxane and water as solvent and in the presence of a base, for example Cs ₂ CO ₃ , at room temperature or by heating up to reflux of solvents. When R3a is COOMe, COOEt, or a protected OH such as O-pivaloyl, deprotection can be performed in STEP 7 by treatment with an aqueous solution of NaOH 2N or LiOH in MeOH. When R3 is COOH, extraction of the product could give the sodium or lithium salt of compound I. The acidification with an aqueous solution of HCl 2N to pH 6-7 could give the neutral form of compound I. The acidification with an aqueous solution of HCl 2N to pH 1-2 could give the hydrochloride salt of compound I. The purification using HPLC in presence of formic acid or trifluoroacetic acid in the eluent could give the formate or trifluoroacetate salt of compound I.

SCHEME 1c: Alternative processes to prepare compounds of the Formula (I) – General process According to SCHEME 1c in which R3a is a hydrogen atom, carboxylic ester such as COOMe, COOEt, or protected OH such as O-pivaloyl, R1, R2, R3, R3’, R3’’, R4, R4’, R6, R7, R8, R9, X, n, m and Y are as defined above, and R5 is a hydrogen atom, compound 1C’ can be converted in STEP 1 to compound 1S in a Suzuki coupling reaction with compound 1R using for example [1,1′-bis(diphenylphosphino) ferrocene]dichloropalladium(II) (Pd(dppf)Cl ₂ ), complex with DCM, as catalyst, in a mixture of dioxane and water and in the presence of a base, for example Cs ₂ CO ₃ , by heating up to reflux of solvent. Compound 1S can be converted in STEP 2 to compound 1N by treatment for example with NaBH ₄ in a solvent such as MeOH. Compound 1N can be converted in STEP 3 to compound 1O by treatment for example with pyridinium tribromide in DCM or THF at room temperature. Compound 1O can be converted in STEP 4 to compound 1T through Suzuki conditions using a suitable boronic reagent R6B(OR’) ₂ or R6BF ₃ K, wherein -B(OR’) ₂ is a boronic acid or a pinacolate ester and R6 is as above defined, using for example [1,1′-bis(diphenylphosphino) ferrocene]dichloropalladium(II) (Pd(dppf)Cl ₂ ), complex with DCM, as catalyst, in a mixture of dioxane and water and in the presence of a base, for example Cs ₂ CO ₃ , by heating up to reflux of solvent. Compound 1T can be converted to compound I by treatment with a source of hydroxide ions such as NaOH or LiOH in solution in MeOH followed by a treatment with sulfuric acid.

SCHEME 1d: Preparation of compounds of the formula (1A) wherein R3a = CO ₂ Me – General process According to SCHEME 1d, in which X, m, R3’, R3” and R9 are as defined above, compound 1A could be commercially available or prepared as follows: compound 1U (commercially available or prepared according to WO2017140669 and WO2018091153) can be converted in STEP 1 to compound 1V by treatment with trifluoromethanesulfonic anhydride, in solution in DCM, in the presence of pyridine as a base. Compound 1V can be converted in STEP 2 to compound 1A by carbonylation with carbon monoxide, in solution in DMF and MeOH, in the presence of a palladium catalyst, for example [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (Pd(dppf)Cl ₂ ), complex with DCM.

SCHEME 1e: Alternative preparation of compounds of the formula (1B) – General process According to SCHEME 1e, in which R3a is a hydrogen atom, a carboxylic ester such as COOMe, COOEt, or protected OH such as O-pivaloyl, R3’, R3”, R9, R6, X and m are as defined above, compound 1B could alternatively be prepared as follows: compound 1A can be converted in STEP 1 to compound 1Aa by treatment with pyridinium tribromide in DCM or THF at room temperature for example. Compound 1Aa can be converted in STEP 2 to compound 1Ab by deprotonation with a base such as LiHMDS in THF followed by treatment with acetic anhydride. Compound 1Ac can be prepared in STEP 3 in a Suzuki coupling reaction between compounds 1Ab and R ₆ B(OR’) ₂ or R ₆ BF ₃ K, wherein -B(OR’) ₂ is a boronic acid or a pinacolate ester and R6 is as above defined, using for example [1,1′-bis(diphenylphosphino) ferrocene]dichloropalladium(II) (Pd(dppf)Cl ₂ ), complex with DCM, as catalyst, in a mixture of toluene and water and in the presence of a base, for example cesium carbonate (Cs ₂ CO ₃ ), by heating up to reflux of solvent. Compound 1Ac can be converted in STEP 4 to compound 1B by hydrolysis with aqueous HCl solution by heating in methanol and DCM for example. SCHEME 1f: Alternative preparation of compounds of the formula (1K) – General process According to SCHEME 1f , in which R3a is a hydrogen atom or a carboxylic ester such as COOMe, COOEt, or protected OH such as O-pivaloyl, and R1, R2, R3, R3’, R3’’, R4, R4’, R5, R6, R7, R8, R9 X, m, n and Y are as defined above, compound 1C can be converted in STEP 1 to compound 1E by treatment for example with bis(pinacolato)diboron, and with a palladium catalyst, for example bis (triphenylphosphine) palladium(II) dichloride Pd(PPh ₃ ) ₂ Cl ₂ , and a phosphine, such as triphenylphosphine, in solution in toluene by heating up to reflux of solvent, in presence of a base such as KOPh. Compound 1W can be prepared in a Suzuki coupling reaction either between compounds 1E and 1R’ in STEP 2 or between compounds 1C and 1R in STEP 3 using for example [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (Pd(dppf)Cl ₂ ), complex with DCM, as catalyst, in a mixture of dioxane and water and in the presence of a base, for example cesium carbonate (Cs ₂ CO ₃ ), by heating up to reflux of solvent. Compound 1W can be converted in STEP 4 to compound 1X by treatment with alkyl magnesium bromide in a solvent such as THF. Compound 1X can be converted in STEP 5 to compound 1K by treatment with sulfuric acid in water. Herein is also provided a process for preparing a compound of formula (I) as defined above, wherein a compound of formula 1K wherein R1, R2, R3’, R3”, R4, R4’, R5, R6, R7, R8, R9, m, n, X and Y are as defined above and R3a is a hydrogen atom, a carboxylic ester such as COOMe, COOEt, or a protected OH such as O-pivaloyl, is converted to compound of formula (I), in presence of a source of hydroxide ions, such as NaOH or LiOH in solution in methanol, said step being optionally preceded by a step for obtaining compound 1K, wherein a compound of formula 1P wherein R1, R2, R3’, R3”, R4, R4’, R5, R6, R7, R8, R9, m, n, X and Y are as defined above and R3a is as defined above, is subjected to a Suzuki coupling with a boronic reagent R6-B(OR’)2 or R6BF3K, wherein -B(OR’) ₂ is a boronic acid or a pinacolate ester and R6 is as defined above. Herein is also provided a process for preparing a compound of formula (I) as defined above, wherein a compound of formula 1Pa wherein R1, R2, R3a, R3’, R3”, R4, R4’, R5, R7, R8, R9, m, n, X and Y are as defined above, is submitted to a Suzuki coupling with a boronic reagent R6B(OR’) ₂ or R6BF3K, wherein -B(OR’)2 is a boronic acid or a pinacolate ester and R6 is defined above, said step being optionally preceded by a step for obtaining compound 1Pa, wherein a compound of formula 1P wherein R1, R2, R3’, R3”, R4, R4’, R5, R7, R8, R9, m, n, X and Y are as defined above and R3a is as defined above, is converted to a compound 1Pa in the presence of a source of hydroxide ions, such as NaOH or LiOH in solution in methanol. Herein are also provided the intermediate compounds selected from compounds of formula 1P, 1K and 1Pa, or any of their pharmaceutically acceptable salt,

wherein R1, R2, R3’, R3”, R4, R4’, R5, R7, R8, R9, m, n, X and Y are as defined above and R3a is a hydrogen atom, a carboxylic ester such as COOMe, COOEt, or protected OH such as O-pivaloyl. Herein is further provided the intermediate compounds of formula 1F and 1D, or any of its pharmaceutically acceptable salt wherein R1, R2, R4, R4’, R5, R7, R8, Y and n are as defined above. The present application also describes the intermediate compound of formula 1E, or any of its pharmaceutically acceptable salt

wherein R3a, R3’, R3”, X, m, R6 and R9 are as defined above. In another aspect, herein is also provided a process for the preparation of a compound of formula (I), wherein R3 is a -COOH group, comprising a deprotection step of a compound of formula 1K as defined above, optionally followed by a purification step. Said purification step may for example consist, as illustrated in step 2 of example 1 herein after, in an acidification step, for example with an aqueous solution of hydrochloric acid. The ¹ H NMR Spectra at 400 and 500 MHz were performed on a Bruker Avance DRX-400 and Bruker Avance DPX-500 spectrometer, respectively, with the chemical shifts (δ in ppm) in the solvent dimethyl sulfoxide-d6 (d6-DMSO) referenced at 2.5 ppm at a temperature of 303 K. Coupling constants (J) are given in Hertz. The liquid chromatography/mass spectra (LC/MS) were obtained on a UPLC Acquity Waters instrument, light scattering detector Sedere and SQD Waters mass spectrometer using UV detection DAD 210-400 nm and flash Acquity UPLC CSH C181.7 µm, dimension 2.1x30 mm, mobile phase H ₂ O + 0.1% HCO ₂ H / CH ₃ CN + 0.1% HCO ₂ H. The following tables 1a and 1b comprise respectively specific compounds of formula (I) (name and structure) in accordance with the present disclosure as well their characterization ( ¹ H NMR and liquid chromatography/mass). Table 1a: Table 1b:

The examples which follow describe the preparation of some compounds of formula (I) described herein. The numbers of the compounds exemplified below match those given in the Tables 1a and 1b above. All reactions are performed under inert atmosphere, unless otherwise stated. In the following examples, when the source of the starting products is not specified, it should be understood that said products are known compounds. Intermediates: Intermediate 1: Methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro- 5H- benzo[7]annulene-3-carboxylate A mixture of methyl 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]an nulene- 3-carboxylate (15 g, 42.82 mmol) (prepared according to WO2017140669), in toluene (150 ml), Pd(PPh3)2Cl ₂ (1.53 g, 2.14 mmol), PPh3 (673.87 mg, 2.57 mmol), bis(pinacolato)diboron (13.38 g, 52.67 mmol) and PhOK (8.04 g, 60.80 mmol) was heated to 75°C for 1.5 h. The yellow suspension becomes orange then brown. After cooling to RT, DCM (150 mL) and water (150 mL) were added, and decantation was done by hydrophobic column. The organic phase was concentrated under reduced pressure. The residue obtained was purified by flash chromatography, eluting with a gradient of heptane/DCM: from 85/15 to 20/80 to give 10.1 g (72%) of methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7- dihydro-5H-benzo[7]annulene-3-carboxylate as a white solid. LC/MS (m/z, MH+): 329 Intermediate 2: Methyl 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan- 2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate Intermediate 2 was prepared following a similar procedure to that of Intermediate 1 from methyl 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6, 7-dihydro-5H- benzo[7]annulene-3-carboxylate (prepared according to WO2020/049153) to give 3.9 g (82%) of methyl 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)- 6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as a white solid. LC/MS (m/z, MH+): 473 Intermediate 3: Methyl 8-(2,4-difluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan- 2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate Step 1: Methyl 6-(2,4-difluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]a nnulene-2- carboxylate Argon is bubbled for 10 minutes in a mixture of 1-bromo-2,4-difluoro-benzene (6.63 g, 34.37 mmol), methyl 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate (5 g, 22.91 mmol), K2CO3 (12.67 g, 91.66 mmol) in toluene (40 ml). After addition of XANTPHOS (1.32 g, 2.29 mmol) and Pd2(dba)3 (1.05 g, 1.15 mmol), the reaction mixture was heated to reflux for 72 hours. After cooling to RT, water (40 ml) and DCM (40 ml) were added. After decantation, the aqueous phase was washed three times with 40 ml of DCM. The combined organic phases were dried over MgSO4, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography, eluting with a gradient of Heptane/EtOAc from 100/00 to 90/10 to give 2.55 g (34%) of methyl 6-(2,4- difluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene -2-carboxylate. LC/MS (m/z, MH+): 331 Step 2: Methyl 8-(2,4-difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6, 7-dihydro-5H- benzo[7]annulene-3-carboxylate To a suspension of NaH (545 mg, 13.62 mmol, 60% purity in wheight) in Me-THF (22 ml) cooled at 5°C was added DBU (277 mg, 0.27 ml, 1.82 mmol) followed by a solution of methyl 6-(2,4-difluorophenyl)-5-oxo-6,7,8,9-tetrahydrobenzo[7]annul ene-2-carboxylate (3 g, 9.08 mmol) and N,N-bis(trifluoromethylsulfonyl)aniline (4.2 g, 11.81 mmol) in THF (25 ml). The cooling bath was removed to allow the temperature to warm up to RT. A mixture of acetic acid (0.4 ml) and water (32 ml) was dropwise added, followed by water (100 ml) and EtOAc (150 ml). After decantation, the organic phase was dried over MgSO ₄ , filtered and concentrated under reduced pressure The residue obtained was purified by flash chromatography, eluting with DCM/heptane 50/50 to give 2.77 g (66%) of methyl 8-(2,4- difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihyd ro-5H-benzo[7]annulene-3- carboxylate. LC/MS (m/z, MH+): 463 Step 3: Methyl 8-(2,4-difluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)-6,7- dihydro-5H-benzo[7]annulene-3-carboxylate Step 3 of Intermediate 3 was prepared following a similar procedure to that of Intermediate 1 from 8-(2,4-difluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6, 7-dihydro-5H- benzo[7]annulene-3-carboxylate to give 1.89 g (72%) of methyl 8-(2,4-difluorophenyl)-9- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H -benzo[7]annulene-3- carboxylate. LC/MS (m/z, MH+): 441 Intermediate 4: Methyl 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxy late Step 1: Methyl 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H- benzo[7]annulene-2-carboxylate Step 1 of Intermediate 4 was prepared following a similar procedure to that of step 1 of Intermediate 3 from 1-bromo-2-methyl-4-fluoro-benzene to give 700 mg (47%) of methyl 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benz o[7]annulene-2- carboxylate. LC/MS (m/z, MH+): 327 Step 2: Methyl 8-(2-methyl-4-fluorophenyl)-9-(((trifluoromethyl)sulfonyl)ox y)-6,7- dihydro-5H-benzo[7]annulene-3-carboxylate Step 2 of Intermediate 4 was prepared following a similar procedure to that of step 2 of Intermediate 3 from methyl 6-(2-methyl-4-fluorophenyl)-5-oxo-6,7,8,9- tetrahydrobenzo[7]annulene-2-carboxylate to give 7.86 g (82%) of methyl 8-(2-methyl-4- fluorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro -5H-benzo[7]annulene-3- carboxylate. LC/MS (m/z, MH+): 459 Step 3: Methyl 8-(2-methyl-4-fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dio xaborolan-2- yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate Step 3 of Intermediate 4 was prepared following a similar procedure to that of Intermediate 1 from methyl 8-(2-methyl-4-fluorophenyl)-9-(((trifluoromethyl)sulfonyl)ox y)-6,7- dihydro-5H-benzo[7]annulene-3-carboxylate to give 3.93g (43%) of methyl 8-(2-methyl-4- fluorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl )-6,7-dihydro-5H- benzo[7]annulene-3-carboxylate. LC/MS (m/z, MH+): 437 Intermediate 5: (4-Bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol Step 1: (4-Bromophenyl)-pyrrolidin-3-yl-methanone, 2,2,2-trifluoroacetic acid To a solution of commercially available tert-butyl 3-(4-bromobenzoyl)pyrrolidine-1- carboxylate (20.3 g, 57.31 mmol) in DCM (100 ml) was added dropwise TFA (100 ml) and the reaction mixture was stirred at RT for 30 minutes. The reaction mixture was concentrated under reduced pressure and the residue obtained was triturated with Et ₂ O. The solid formed was filtered to give 17 g (81%) of (4-bromophenyl)-pyrrolidin-3-yl-methanone; 2,2,2- trifluoroacetic acid. LC/MS (m/z, MH+): 254 Step 2: (4-Bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone A mixture of (4-bromophenyl)-pyrrolidin-3-yl-methanone, 2,2,2-trifluoroacetic acid (9.45 g, 25.67 mmol), K ₂ CO ₃ (10.64 g, 77 mmol), 1-fluoro-3-iodo-propane (5.07 g, 26.95 mmol) in MeCN (200 ml) was heated at 80°C for 3 hours. The reaction mixture was quenched by addition of a saturated solution of NH4Cl (200 ml) and extracted with EtOAc (3 x 200 ml). The organic phase was washed with brine (200 ml), dried over Na2SO4 filtered and concentrated under reduced pressure and the residue obtained was purified by flash chromatography, eluting with a gradient of DCM / MeOH: from 100/00 to 50/50 to 90/10 to give 6.34 g (78%) of (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone . LC/MS (m/z, MH+): 314 Step 3: (4-Bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol To a mixture of (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone (6.31 g, 20.07 mmol) in MeOH (180ml) was added NaBH4 (2.28 g, 60.21 mmol) and the mixture was stirred at RT for 2 hours. A concentrated solution of NH ₄ Cl (100 ml) and EtOAc (300 ml) were added. After decantation, the organic phase was washed with brine (200 ml), dried over Na2SO4 filtered and concentrated under reduced pressure to give 6.69 g (crude) of (4- bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol. LC/MS (m/z, MH+): 316 Intermediate 6: 3-[(4-Bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine Cis isomer To a mixture of (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanol (Intermediate 5) (5.16 g, 16.33 mmol) and water (10 ml) was added dropwise at 0°C, sulfuric acid (35 ml). The cooling bath was removed, and the reaction mixture was stirred for 1 hour at RT. The reaction mixture was poured to a mixture of ice and water (500 ml). Powder NaHCO ₃ was added to pH 9. EtOAc (300 ml) was added and the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of DCM/EtOAc: from 100/00 to 00/100 to give 4.13 g (85%) 3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine as a mixture of Cis and Trans isomers. The mixture of Cis and Trans isomers of 3-[(4-bromophenyl)methylene]-1-(3- fluoropropyl)pyrrolidine was separated by preparative SFC by using a IF 5x25cm, 5µm column (Daicel) and a CO ₂ mobile phase with 30% of a 0.1% TEA in MeOH solution as co-solvent. The temperature was set at 40°C and the back pressure regulator at 100 bars to give 1145 mg of Cis isomer (3Z)-3-[(4-bromophenyl)methylene]-1-(3- fluoropropyl)pyrrolidine and 2584 mg of Trans isomer (3E)-3-[(4- bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolidine. LC/MS (m/z, MH+): 298 Intermediate 7: (4-Bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]metha nol Step 1: 3,3-Difluoropropyl 4-methylbenzenesulfonate To a solution of 3,3-difluoropropan-1-ol (500 mg, 5.20 mmol) in THF (10 ml) cooled at 0°C, was added NaH (229 mg, 5.72 mmol, 60 mass%). After 1 hour of stirring at 0°C, 4- methylbenzenesulfonyl chloride (1.03 g, 4.13 mmol) was added and the reaction mixture was stirred for 1 hour at RT. The reaction mixture was quenched by addition of a saturated solution of NH ₄ Cl (20 ml) and extracted with EtOAc (3 x 20 ml). The organic phase was washed with brine (20 ml), dried over Na ₂ SO ₄ filtered and concentrated under reduced pressure and the residue obtained was purified by flash chromatography, eluting with DCM to give 1.03 g (79%) of 3,3-difluoropropyl 4-methylbenzenesulfonate. LC/MS (m/z, MH+): 251 Step 2: (4-Bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]metha none Step 2 of Intermediate 7 was prepared following a similar procedure to that of step 2 of Intermediate 5 from (4-bromophenyl)-pyrrolidin-3-yl-methanone, 2,2,2-trifluoroacetic acid and 3,3-difluoropropyl 4-methylbenzenesulfonate to give 6.29 g (70%) of (4-bromophenyl)- [1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanone. LC/MS (m/z, MH+): 332 Step 3: (4-Bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]metha nol Step 3 of Intermediate 7 was prepared following a similar procedure to that of step 3 of Intermediate 5 from (4-bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]metha none to give 5.53 g (crude) of (4-bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]metha nol. LC/MS (m/z, MH+): 334 Intermediate 8: 3-[(4-Bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrrolidi ne Cis isomer Intermediate 8 was prepared following a similar procedure to that of Intermediate 6 from (4- bromophenyl)-[1-(3,3-difluoropropyl)pyrrolidin-3-yl]methanol (Intermediate 7) to give 2.71 g (64%) 3-[(4-bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrrolidi ne as a mixture of Cis and Trans isomers. The mixture of Cis and Trans isomers of 3-[(4-bromophenyl)methylene]-1-(3- fluoropropyl)pyrrolidine was separated by preparative SFC by using a IG 5x25cm, 5µm column (Daicel) and a CO ₂ mobile phase with 30% of a 0.1% TEA in MeOH solution as cosolvent. The temperature was set at 40°C and the back pressure regulator at 100 bars to give 158 mg of Cis isomer (3Z)-3-[(4-bromophenyl)methylene]-1-(3,3- difluoropropyl)pyrrolidine and 299 mg of Trans isomer (3E)-3-[(4- bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrrolidine. LC/MS (m/z, MH+): 316 Intermediate 9: Methyl (Z)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate Step 1: Methyl 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phe nyl)-6,7- dihydro-5H-benzo[7]annulene-3-carboxylate A mixture of methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro- 5H- benzo[7]annulene-3-carboxylate (Intermediate 1) (3.42, 10.44 mmol), (4-bromophenyl)-[1- (3-fluoropropyl)pyrrolidin-3-yl]methanol (Intermediate 5) (3 g, 9.49 mmol) Cs ₂ CO ₃ (8.04 g, 24.67 mmol), Pd(dppf)Cl2 complex with DCM (466 mg, 0.57 mmol), in dioxane (24 ml) and water (6 ml) was heated to reflux for 1 hour. The reaction mixture was quenched by addition of a saturated solution of NH4Cl (50 ml) and extracted with EtOAc (3 x 50 ml). The organic phase was washed with brine (50 ml), dried over Na ₂ SO ₄ filtered and concentrated under reduced pressure and the residue obtained by flash chromatography, eluting with a gradient of DCM/MeOH: from 100/00 to 80/20 to give 2.59 g (62%) of methyl 9-(4-((1-(3- fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-6,7-dih ydro-5H-benzo[7]annulene- 3-carboxylate. LC/MS (m/z, MH+): 438 Step 2: Methyl 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3- yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylate To a mixture of methyl 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phe nyl)- 6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (2.60 g, 5.94 mmol) in DCM (100 ml) was added pyridinium tribromide (2.66 g, 8.31 mmol). The reaction mixture was stirred for 18 hours at RT. The reaction was quenched with concentrated solution of NaHCO ₃ (100 ml) and DCM (150 ml). The organic phase was dried over Na ₂ SO ₄ , filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of DCM/MeOH: from 100/00 to 80/20 to give 1.53 g (50%) of methyl 8-bromo- 9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phe nyl)-6,7-dihydro-5H- benzo[7]annulene-3-carboxylate. LC/MS (m/z, MH+): 516 Step 3: Methyl (Z)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)me thyl)phenyl)- 6,7-dihydro-5H-benzo[7]annulene-3-carboxylate

To a mixture of methyl 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3- yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylate (1.53 g, 2.97 mmol) and water (2 ml) was added dropwise at 0°C, sulfuric acid (7 ml). the cooling bath was removed and the reaction mixture was stirred for 30 minutes at RT. The reaction mixture was poured to a mixture of ice and water (150 ml). Powder NaHCO ₃ was added to pH 9. EtOAc (100 ml) was added and the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the residue obtained was purified by flash chromatography eluting with a gradient of DCM/EtOAc: from 100/00 to 00/100 to give 1.04 g (69%) of methyl 8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-ylidene)methyl )phenyl)- 6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as a mixture of Cis and Trans isomers. The mixture of Cis and Trans isomers of methyl 8-bromo-9-(4-((1-(3- fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro -5H-benzo[7]annulene-3- carboxylate was separated by preparative SFC by using a IB-N5 5x25cm, 5µm column (Daicel) and a CO ₂ mobile phase with 23% of a 0.1% TEA in MeOH solution as cosolvent. The temperature was set at 40°C and the back pressure regulator at 100 bars to give 170 mg of Cis isomer methyl (Z)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate and 388 mg of Trans isomer methyl (E)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate. LC/MS (m/z, MH+): 498 Intermediate 10: Methyl (Z)-8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate

Step 1: Methyl 9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl )phenyl)-6,7- dihydro-5H-benzo[7]annulene-3-carboxylate Step 1 of Intermediate 10 was prepared following a similar procedure to that of step 1 of Intermediate 9 from methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro- 5H-benzo[7]annulene-3-carboxylate (Intermediate 1) and (4-bromophenyl)-[1-(3,3- difluoropropyl)pyrrolidin-3-yl]methanol (Intermediate 7) to give 5.98 g (80%) of methyl 9- (4-((1-(3,3-difluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)p henyl)-6,7-dihydro-5H- benzo[7]annulene-3-carboxylate. LC/MS (m/z, MH+): 456 Step 2: Methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3- yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylate Step 2 of Intermediate 10 was prepared following a similar procedure to that of step 2 of Intermediate 9 from methyl 9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3- yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylate to give 3.93 g (56%) of methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3- yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylate. LC/MS (m/z, MH+): 534 Step 3: Methyl (Z)-8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate Step 3 of Intermediate 10 was prepared following a similar procedure to that of step 3 of Intermediate 9 from methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3- yl)(hydroxy)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3 -carboxylate to give 2.46 g (65%) of methyl 8-bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate as a mixture of Cis and Trans isomers. The mixture of Cis and Trans isomers of methyl 8-bromo-9-(4-((1-(3,3- difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihyd ro-5H-benzo[7]annulene-3- carboxylate was separated by chiral chromatography: Chiralpak AD 20 µM (250 x 4.6 mm) eluting with heptane/EtOH/TEA : 50/50/0.1 to give 562 mg of Cis isomer methyl (Z)-8- bromo-9-(4-((1-(3,3-difluoropropyl)pyrrolidin-3-ylidene)meth yl)phenyl)-6,7-dihydro-5H- benzo[7]annulene-3-carboxylate and 986 mg of Trans isomer methyl (E)-8-bromo-9-(4-((1- (3,3-difluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7- dihydro-5H- benzo[7]annulene-3-carboxylate. LC/MS (m/z, MH+): 516 Intermediate 11: 2-(8-(2-Chlorophenyl)-6,7-dihydro-5 H-benzo[7]annulen-9-yl)-4,4,5,5- tetramethyl-1,3,2-dioxaborolane Step 1: 6-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-o ne Step 1 of Intermediate 11 was prepared following a similar procedure to that of Step 1 of Intermediate 3 from 1-bromo-2-chloro-benzene and and 6,7,8,9-tetrahydrobenzo[7]annulen- 5-one to give 580 mg (16%) of 6-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen- 5-one. LC/MS (m/z, MH+): 271 Step 2: 8-(2-Chlorophenyl)-6,7-dihydro-5H-benzo[7]annulen-9-yl trifluoromethanesulfonate Step 2 of Intermediate 11 was prepared following a similar procedure to that of Step 2 of Intermediate 3 from 6-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-o neto give 608 mg (71%) of 8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulen-9-yl trifluoromethanesulfonate. LC/MS (m/z, MH+): 403 Step 3: 2-(8-(2-Chlorophenyl)-6,7-dihydro-5 H-benzo[7]annulen-9-yl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane Step 3 of Intermediate 11 was prepared following a similar procedure to that of Intermediate 1 from 8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulen-9-yl trifluoromethanesulfonate to give 430 mg (84%) of 2-(8-(2-chlorophenyl)-6,7-dihydro-5 H-benzo[7]annulen-9-yl)- 4,4,5,5-tetramethyl-1,3,2-dioxaborolane. LC/MS (m/z, MH+): 381 Intermediate 12: Methyl 4-(2,4-dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-2,3-dihydrobenzo[b]oxepine-8-carboxylate Step 1: 5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepine-8-yl trifluoromethanesulfonate To a mixture of 8-hydroxy-3,4-dihydrobenzo[b]oxepine-5(2H)-one (4.2 g, 23.57 mmol) (prepared according to WO2018091153) and pyridine (2.82 g, 2.89 ml, 35.36 mmol) in DCM (120 ml) cooled at -20°C was dropwise added trifluoromethanesulfonic anhydride (8.14 g, 6 ml, 28.28 mmol). The reaction mixture was stirred at 0°C for 30 minutes. Water (50 ml) was added. The organic phase was separated and washed with an aqueous saturated solution of NaHCO ₃ (50 ml). The organic phase was dried over MgSO ₄ , filtered, and concentrated under reduced pressure to give 7.40 g (crude) of 5-oxo-2,3,4,5- tetrahydrobenzo[b]oxepine-8-yl trifluoromethanesulfonate. LC/MS (m/z, MH+): 311 Step 2: Methyl 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepine-8-carboxylate To a solution of compound 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepine-8-yl trifluoromethanesulfonate (7.4 g, 23.85 mmol) in DMF (30 ml) and MeOH (15 ml) was added DIEA (3.15 g, 4.16 ml, 23.85 mmol) and Pd(dppf)Cl ₂ complex with DCM (1.10 g, 1.43 mmol), the suspension was degassed and purged three times with CO. The mixture was stirred under CO (5 bars) at 75 °C for 2 hours. The reaction was filtered through celite. The filtrate was diluted with water (400 ml) and extracted three times with EtOAc (300 ml). The combined organic phases were dried over Na2SO4, filtered, concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of heptane/ethyl acetate: from 85/15 to 80/20 to give 4.6 g (88%) methyl 5-oxo- 2,3,4,5-tetrahydrobenzo[b]oxepine-8-carboxylate. LC/MS (m/z, MH+): 221 Step 3: Methyl 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepi ne-8- carboxylate Step 3 of Intermediate 12 was prepared following a similar procedure to that of step 1 of Intermediate 3 from methyl 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepine-8-carboxylate to give 1.13 g (67%) of methyl 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepi ne-8- carboxylate. LC/MS (m/z, MH+): 365 Step 4: Methyl 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2, 3- dihydrobenzo[b]oxepine-8-carboxylate Step 4 of Intermediate 12 was prepared following a similar procedure to that of step 2 of Intermediate 3 from methyl 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5- tetrahydrobenzo[b]oxepine-8-carboxylate to give 0.48 g (31%) of methyl 4-(2,4- dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihyd robenzo[b]oxepine-8- carboxylate. LC/MS (m/z, MH+): 496 Step 5: Methyl 4-(2,4-dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)-2,3- dihydrobenzo[b]oxepine-8-carboxylate Step 5 of Intermediate 12 was prepared following a similar procedure to that of Intermediate 1 from methyl 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2, 3- dihydrobenzo[b]oxepine-8-carboxylate to give 260 mg (61%) of methyl 4-(2,4- dichlorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-2,3- dihydrobenzo[b]oxepine-8-carboxylate. LC/MS (m/z, MH+): 271 Intermediate 13: 8-(2,4-Dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6, 7-dihydro- 5H-benzo[7]annulen-3-yl pivalate Step 1: 6-(2,4-Dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo [7]annulen-5-one A mixture of 1-bromo-2,4-dichloro-benzene (890 mg, 3.94 mmol), 2-methoxy-6,7,8,9- tetrahydro-5H-benzo[7]annulen-5-one (500 mg; 2.63 mmol), XANTPHOS (0.304 g, 0.53 mmol) and Pd ₂ (dba) ₃ (0.3 g, 0.53 mmol) in xylene (10 ml) was heated to reflux for 16 hours. After cooling to RT, water (50 ml) and Et ₂ O (50 ml) were added. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography, eluting with a gradient of cyclohexane/EtOAc from 100/00 to 95/05 to give 470 mg (42%) of 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9- tetrahydro-5H-benzo[7]annulen-5-one. LC/MS (m/z, MH+): 335 Step 2: 6-(2,4-Dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo [7]annulen-5-one A mixture of 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo [7]annulen-5- one (470 mg, 1.23 mmol) and aluminium chloride (395 mg, 2.96 mmol) in toluene (8 ml) was heated at 90°C for 2 hours. After cooling to room temperature, water (20 ml) and EtOAc (50 ml) were added. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography, eluting with a gradient of cyclohexane/EtOAc from 100/00 to 80/20 to give 165 mg (42%) of 6- (2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7 ]annulen-5-one. LC/MS (m/z, MH+): 321 Step 3: 6-(2,4-Dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]a nnulen-2-yl pivalate A mixture of 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo [7]annulen-5- one (163 mg, 0.51 mmol), K ₂ CO ₃ (77 mg, 0.56 mmol) and pivaloyl chloride (67 mg, 0.56 mmol) in acetone (5 ml) was heated at 40°C for 1 hour. After cooling to RT, the reaction mixture was filtered. The filtrate was concentrated under reduced pressure and the residue obtained was purified by flash chromatography with a gradient of cyclohexane/EtOAc from 100/00 to 90/10 to give 205 mg (96%) of 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro- 5H-benzo[7]annulen-2-yl pivalate. LC/MS (m/z, MH+): 405 Step 4: 8-(2,4-Dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6, 7-dihydro-5 H- benzo[7]annulen-3-yl pivalate To a solution of 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]a nnulen-2-yl pivalate (197 mg, 0.48 mmol) in THF (5 ml) was added KHMDS (1 M, 0.58 ml, 0.58 mmol) at -50°C under Ar atmosphere. The mixture was stirred for 30 min and 1,1,1-trifluoro-N- phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (173 mg, 0.49 mmol) was added to the resulting mixture. The reaction mixture was slowly warmed up to 20°C and stirred for 90 minutes. The reaction mixture was quenched with saturated aqueous citric acid solution, then diluted with water and extracted twice with Et ₂ O. The combined organic layers were dried over anhydrous Na ₂ SO ₄ , filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography with a gradient of cyclohexane/EtOAc from 100/00 to 90/10 to give 160 mg (61%) of 8-(2,4-dichlorophenyl)-9- (((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5 H-benzo[7]annulen-3-yl pivalate. LC/MS (m/z, MH+): 537 Intermediate 14: (3Z)-1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dio xaborolan-2- yl)phenyl]methylene]pyrrolidine A mixture of (3Z)-3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolid ine (Intermediate 6) (200 mg, 0.67 mmol), in dioxane (4 ml), Pd(PPh ₃ ) ₂ Cl ₂ (38 mg, 0.07 mmol), bis(pinacolato)diboron (221 mg, 0.87 mmol) and AcOK (164 mg, 1.68 mmol) was heated at reflux for 2 hours. After cooling, the reaction mixture was filtered on dicalite. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography, eluting with a gradient of DCM/EtOAc/EtOH: from 100/00/00 to 75/20/05 to give 160 mg (69%) of (3Z)-1-(3-fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl]methylene]pyrrolidine. LC/MS (m/z, MH+): 346 Intermediate 15: (3Z)-1-(3,3-difluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2 - dioxaborolan-2-yl)phenyl]methylene]pyrrolidine Intermediate 15 was prepared following a similar procedure to that of Intermediate 14 from (3Z)-3-[(4-bromophenyl)methylene]-1-(3,3-difluoropropyl)pyrr olidine (Intermediate 8) to give 114.8 mg (87%) of (3Z)-1-(3,3-difluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2 - dioxaborolan-2-yl)phenyl]methylene]pyrrolidine. LC/MS (m/z, MH+): 364 Intermediate 16: Methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8- dihydronaphthalene-2-carboxylate Step 1: Methyl 2-(2,4-dichlorophenyl)-1-oxo-tetralin-6-carboxylate Step 1 of Intermediate 16 was prepared following a similar procedure to that of step 1 of Intermediate 3 from methyl 1-oxotetralin-6-carboxylate to give 459 mg (19%) of methyl 4- (2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepine -8-carboxylate. LC/MS (m/z, MH+): 349 Step 2: Methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8- dihydronaphthalene-2-carboxylate Step 2 of Intermediate 16 was prepared following a similar procedure to that of step 2 of Intermediate 3 from methyl 2-(2,4-dichlorophenyl)-1-oxo-tetralin-6-carboxylate to give 0.48 g (31%) of methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8- dihydronaphthalene-2-carboxylate. LC/MS (m/z, MH+): 481 Intermediate 17: (Z)-3-(4-Bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrol idine Step 1: Tert-butyl 3-(4-bromo-2-fluorobenzoyl)pyrrolidine-1-carboxylate To a solution of 1,4-dibromo-2-fluoro-benzene (11.3 g, 44.52 mmol) in THF (60 ml) cooled at -78°C, was dropwise added n-BuLi 2.5 M (18 ml, 44.52 mmol). After stirring for 45 minutes at -78°C, a solution of tert-butyl 3-[methoxy(methyl)carbamoyl]pyrrolidine-1- carboxylate (10 g, 38.71 mmol) in THF (60 ml) was dropwise added. The cooling bath was removed and the reaction mixture was stirred for 18 hours at RT. The reaction mixture was poured into a mixture of saturated NH4Cl aqueous solution (200 ml) and EtOAc (300 ml). After decantation, the organic layers were dried over anhydrous Na ₂ SO ₄ , filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography with a gradient of DCM/EtOAc from 100/0 to 80/20 to give 2.27 g (13%) of tert-butyl 3-(4- bromo-2-fluorobenzoyl)pyrrolidine-1-carboxylate. LC/MS (m/z, MH+): 372 Step 2: (4-Bromo-2-fluorophenyl)(pyrrolidin-3-yl)methanone, 2,2,2-trifluoroacetic acid Step 2 of Intermediate 17 was prepared following a similar procedure to that of step 1 of Intermediate 5 from tert-butyl 3-(4-bromo-2-fluorobenzoyl)pyrrolidine-1-carboxylate to give 1.96 g (84%) of (4-bromo-2-fluorophenyl)(pyrrolidin-3-yl)methanone, 2,2,2- trifluoroacetic acid. LC/MS (m/z, MH+): 272 Step 3: (4-Bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)m ethanone Step 3 of Intermediate 17 was prepared following a similar procedure to that of step 2 of Intermediate 5 from (4-bromo-2-fluorophenyl)(pyrrolidin-3-yl)methanone, 2,2,2- trifluoroacetic acid to give 1.13 g (67%) of (4-bromo-2-fluorophenyl)(1-(3- fluoropropyl)pyrrolidin-3-yl)methanone. LC/MS (m/z, MH+): 332 Step 4: (4-Bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)m ethanol Step 4 of Intermediate 17 was prepared following a similar procedure to that of step 3 of Intermediate 5 from (4-bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3- yl)methanone to give 2.1 g (97%) of (4-bromo-2-fluorophenyl)(1-(3- fluoropropyl)pyrrolidin-3-yl)methanol. LC/MS (m/z, MH+): 334 Step 5: (Z)-3-(4-Bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrol idine Step 5 of Intermediate 17 was prepared following a similar procedure to that of Intermediate 6 from (4-bromo-2-fluorophenyl)(1-(3-fluoropropyl)pyrrolidin-3-yl)m ethanol to give 925 mg of 3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrolidin e as a mixture of Cis and Trans isomers. The mixture of Cis and Trans isomers of 3-(4-bromo-2-fluorobenzylidene)-1-(3- fluoropropyl)pyrrolidine was separated by chiral chromatography: Chiralpak AD 20 µm (250 x 4.6 mm) eluting with heptane/EtOH/TEA : 95/05/0.1 to give 510 mg of Trans isomer (E)-3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrol idine and 248 mg of Cis isomer (Z)-3-(4-bromo-2-fluorobenzylidene)-1-(3-fluoropropyl)pyrrol idine. LC/MS (m/z, MH+): 316 Intermediate 18: [1-(3-Fluoropropyl)pyrrolidin-3-yl]-[4-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan-2-yl)phenyl]methanone Intermediate 18 was prepared following a similar procedure to that of Intermediate 14 from (4-bromophenyl)-[1-(3-fluoropropyl)pyrrolidin-3-yl]methanone (Step 2 of Intermediate 5) to give 2.4 g (100%) of [1-(3-fluoropropyl)pyrrolidin-3-yl]-[4-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan-2-yl)phenyl]methanone. LC/MS (m/z, MH+): 362 Method A: Example 1: (Z)-8-(2,4-Dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid, hydrochloride Step 1: Methyl (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate A mixture of methyl 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2- yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (Intermediate 2) (261.8 mg, 0.23 mmol), (3Z)-3-[(4-bromophenyl)methylene]-1-(3-fluoropropyl)pyrrolid ine (Intermediate 6) (150 mg, 0.50 mmol), Cs2CO3 (426 mg, 1.31 mmol), and Pd(dppf)Cl ₂ , complex with DCM (25.8 mg, 0.03 mmol) in dioxane (4 ml) and water (1 ml) was heated to reflux 1 hour. After cooling to RT, water (10 ml) and EtOAc (20 ml) were added. After decantation, the organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with cyclohexane/EtOAc 50/50 to give 131 mg (46%) of methyl (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3- fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-6,7-dihydro -5H-benzo[7]annulene-3- carboxylate. LC/MS (m/z, MH+): 564 Step 2: (Z)-8-(2,4-Dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid, hydrochloride To a solution of methyl (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate (131 mg, 0.22 mmol) in MeOH (2 ml), THF (1 ml) and water (0.5 ml) was added LiOH (53.86 mg, 2.25 mmol) and the reaction mixture was stirred at RT for 24 hours. The reaction mixture was concentrated under reduced pressure. To the residue obtained, addition of water (and HCl 1N till pH 1-2. The solid formed was filtered, washed with Et ₂ O and oven dried to give 81.5 mg (62%) of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid, hydrochloride. Method B: Example 2: (Z)-8-(2-Chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)p yrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid Step 1: Methyl (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyr rolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate A mixture of methyl (Z)-8-bromo-9-(4-((1-(3-fluoropropyl)pyrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate (Intermediate 9) (87 mg, 0.17 mmol), (2-chloro-4-fluoro-phenyl)boronic acid (36.5 mg, 0.21 mmol), Cs ₂ CO ₃ (148 mg, 0.45 mmol), and Pd(dppf)Cl ₂ , complex with DCM (8.55 mg, 0.01 mmol) in dioxane (4 ml) and water (1 ml) was heated at reflux for 1 hour. After cooling to RT, the reaction mixture was quenched with saturated solution of NH ₄ Cl (5 ml) and EtOAc (20 ml). After decantation, the organic phase was dried over Na ₂ SO ₄ , filtered, concentrated under reduced pressure and the residue was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/00 to 80/20 to give 53 mg (55%) of methyl (Z)-8-(2- chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3 -ylidene)methyl)phenyl)-6,7- dihydro-5H-benzo[7]annulene-3-carboxylate. LC/MS (m/z, MH+): 548 Step 2: (Z)-8-(2-Chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)p yrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid Step 2 of Example 2 was prepared following a similar procedure to that of step 2 of Example 1 from methyl (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3-fluoropropyl)pyr rolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylate to give 33 mg (66%) of (Z)-8-(2-chloro-4-fluorophenyl)-9-(4-((1-(3,3-fluoropropyl)p yrrolidin-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-car boxylic acid. Method C: Example 24: (Z)-6-(2,4-Dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid, hydrochloride Step 1: Methyl (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylate A mixture of methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8- dihydronaphthalene-2-carboxylate (Intermediate 16) (280 mg, 0.28 mmol), (3Z)-1-(3- fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2- yl)phenyl]methylene]pyrrolidine (Intermediate 14) (151 mg, 0.44 mmol), Cs ₂ CO ₃ (486 mg, 1.49 mmol), and Pd(dppf)Cl ₂ , complex with DCM (43 mg, 0.05 mmol) in dioxane (3 ml) and water (1.21ml) was heated at reflux for 30 minutes. After cooling to RT, water (2 ml) and DCM (10 ml) were added. After decantation on hydrophobic column, the organic phase was dried over Na ₂ SO ₄ , filtered, concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/00 to 95/05 to give 123 mg (51%) of methyl (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3- fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-7,8-dihydro naphthalene-2-carboxylate. LC/MS (m/z, MH+): 550 Step 2: (Z)-6-(2,4-Dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid, hydrochloride Step 2 of Example 24 was prepared following a similar procedure to that of step 2 of Example 1 from methyl (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-7,8-dihydronaphthalene-2-carboxylate to give 113 mg (88%) of (Z)-6-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3-ylidene)methyl)phenyl)- 7,8-dihydronaphthalene-2-carboxylic acid, hydrochloride. Method D: Example 16: (Z)-8-(2,4-Dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-ol, hydrochloride Step 1: (Z)-8-(2,4-Dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate

A mixture of 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6, 7-dihydro-5H- benzo[7]annulen-3-yl pivalate (Intermediate 13) (60 mg, 0.11 mmol), (3Z)-1-(3- fluoropropyl)-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2- yl)phenyl]methylene]pyrrolidine (Intermediate 14) (40 mg, 0.11 mmol), Cs ₂ CO ₃ (91 mg, 0.28 mmol), and Pd(dppf)Cl ₂ , complex with DCM (6 mg, 0.008 mmol) in dioxane (2 ml) and water (0.51ml) was heated to reflux for 30 minutes. After cooling to RT, water (5 ml) and EtOAc (10 ml) were added. After decantation, the organic phase was dried over Na ₂ SO ₄ , filtered, concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of cyclohexane/EtOAc from 90/10 to 80/20 to give 31 mg (46%) of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate. LC/MS (m/z, MH+): 607 Step 2: (Z)-8-(2,4-Dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-ol, hydrochloride To a solution of (Z)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate (31 mg, 0.04 mmol) in MeOH (2 ml) was added NaOH (6.8 mg, 0.17 mmol) and the reaction mixture was stirred at RT for 30 minutes. The reaction mixture was concentrated under reduced pressure. To the residue obtained, water (5 ml) and HCl 1N till pH 1-2 were added followed by DCM (10 ml). After decantation, the organic phase was dried over Na ₂ SO ₄ , filtered, concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/00 to 95/05 to give 5.6 mg (17%) of (Z)- 8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3 -ylidene)methyl)phenyl)-6,7- dihydro-5H-benzo[7]annulen-3-ol, hydrochloride. Method E: Example 30: (Z)-4-(2,4-Dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-ol Step 1: 5-(4-(1-(3-Fluoropropyl)pyrrolidine-3-carbonyl)phenyl)-2,3- dihydrobenzo[b]thiepin-8-yl pivalate Step 1 of Example 30 was prepared following a similar procedure to that of step 1 of Example 16 from 5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]thiepi n-8-yl pivalate (prepared according to WO2018091153) and [1-(3-fluoropropyl)pyrrolidin-3-yl]- [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]metha none (Intermediate 18) to give 2.7 g (86%) of 5-(4-(1-(3-fluoropropyl)pyrrolidine-3-carbonyl)phenyl)-2,3- dihydrobenzo[b]thiepin-8-yl pivalate. LC/MS (m/z, MH+): 496 Step 2: 5-(4-((1-(3-Fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phe nyl)-2,3- dihydrobenzo[b]thiepin-8-yl pivalate Step 2 of Example 30 was prepared following a similar procedure to that of Step 3 of Intermediate 5 from 5-(4-(1-(3-fluoropropyl)pyrrolidine-3-carbonyl)phenyl)-2,3- dihydrobenzo[b]thiepin-8-yl pivalate to give 980 mg (36%) of 5-(4-((1-(3- fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dih ydrobenzo[b]thiepin-8-yl pivalate. LC/MS (m/z, MH+): 498 Step 3: 4-Bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)me thyl)phenyl)-2,3- dihydrobenzo[b]thiepin-8-yl pivalate Step 3 of Example 30 was prepared following a similar procedure to that of Step 2 of Intermediate 9 from 5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phe nyl)-2,3- dihydrobenzo[b]thiepin-8-yl pivalate to give 650 mg (56%) of 4-bromo-5-(4-((1-(3- fluoropropyl)pyrrolidin-3-yl)(hydroxy)methyl)phenyl)-2,3-dih ydrobenzo[b]thiepin-8-yl pivalate. LC/MS (m/z, MH+): 576 Step 4: 4-(2,4-Dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3 - yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-yl pivalate Step 4 of Example 30 was prepared following a similar procedure to that of Step 1 of Example 2 from 4-bromo-5-(4-((1-(3-fluoropropyl)pyrrolidin-3- yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-yl pivalate to give 700 mg (97%) of 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3 - yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-yl pivalate. LC/MS (m/z, MH+): 642 Step 5: 4-(2,4-Dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3 - yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-ol To a solution of 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3 - yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-yl pivalate (724 mg, 1.09 mmol) in MeOH (5 ml) was added NaOH 5N (0.65 ml, 3.3 mmol) and the reaction mixture was stirred at RT for 30 minutes. The reaction mixture was concentrated under reduced pressure. To the residue obtained, water (5 ml) and HCl 1N till pH 7 were added followed by DCM (20 ml). After decantation, the organic phase was dried over Na ₂ SO ₄ , filtered, concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/00 to 90/10 to give 570 mg (91%) of 4- (2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-y l)(hydroxy)methyl)phenyl)- 2,3-dihydrobenzo[b]thiepin-8-ol. LC/MS (m/z, MH+): 558 Step 5: (Z)-4-(2,4-Dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolid in-3- ylidene)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-ol To a mixture of 4-(2,4-dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3 - yl)(hydroxy)methyl)phenyl)-2,3-dihydrobenzo[b]thiepin-8-ol (560 mg, 1 mmol) in water (1.3 ml) cooled at 0 °C was added dropwise sulfuric acid (11 ml, 207 mmol). The cooling bath was removed, and the reaction mixture was stirred for 18 hour at RT and 1.5 hour at 50 °C. The reaction mixture was poured into a mixture of ice and water (500 ml). Powder NaHCO ₃ was added to pH 9 followed by EtOAc (300 ml) and the organic phase was separated and dried over Na ₂ SO ₄ , filtered, concentrated under reduced pressure and the residue purified by flash chromatography eluting with a gradient of DCM/MeOH from 100/00 to 95/05 to give 11 mg (2%) of 4-(2,4-dichlorophenyl)-5-(4-((1-(3- fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydro benzo[b]thiepin-8-ol as a mixture of (Z) and (E) isomers. The mixture of (Z) and (E) isomers of 4-(2,4-dichlorophenyl)-5-(4-((1-(3- fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihydro benzo[b]thiepin-8-ol was separated on column I-Cellulose 5 µm (eq phenomenex Chiralpak IC) (0.3X25 cm), eluting with heptane/EtOH/TEA (90/10/0.1) to give 2.7 mg of (Z) isomer (Z)-4-(2,4- dichlorophenyl)-5-(4-((1-(3-fluoropropyl)pyrrolidin-3-yliden e)methyl)phenyl)-2,3- dihydrobenzo[b]thiepin-8-ol and 4.1 mg of (E) isomer (E)-4-(2,4-dichlorophenyl)-5-(4-((1- (3-fluoropropyl)pyrrolidin-3-ylidene)methyl)phenyl)-2,3-dihy drobenzo[b]thiepin-8-ol. The compounds according to Table 1a above were subjected to pharmacological tests for determining their degradation effects on estrogen receptors. Test: Estrogen receptor degradation activity Said test involves measuring the in vitro degradation activity of the compounds of the Table 1a. The measurements of the degradation activities were made using a breast cancer cell ERα in cell western assay as described hereunder. MCF7 cells (ATCC) were seeded in 384 wells microplate (collagen coated) at a concentration of 10000 cells/ 30 µL per well in red phenol free MEM alpha medium (invitrogen) containing 5% charcoal dextran striped FBS. The following day, 9 points serial 1:5 dilution of each compound was added to the cells in 2.5µL at final concentrations ranging from 0.3-0.0000018 µM (in table 2), or 0.1 µM for fulvestrant (using as positive control). At 4 hours post compound addition the cells were fixed by adding 25 µL of formalin (final concentration 5% formalin containing 0.1% triton) for 10 minutes at room temperature and then washed twice with PBS. Then, 50 µL of LI-COR blocking buffer containing 0.1% Triton was added to plate for 30 minutes at room temperature. LI-COR blocking buffer was removed and cells were incubated overnight at cold room with 50 µL anti-ER rabbit monoclonal antibody (Thermo scientific MA1-39540) diluted at 1:1000 in LI-COR blocking buffer containing 0.1% tween-20. Wells which were treated with blocking buffer but no antibody were used as background control. Wells were washed twice with PBS (0.1% tween- 20) and incubated at 37 °C for 60 minutes in LI-COR (0.1% tween-20) containing goat anti- rabbit antibody Alexa 488 (1:1000) and Syto-64 a DNA dye (2 µM final concentration). Cells were then washed 3 times in PBS and scanned in ACUMEN explorer (TTP-Labtech). Integrated intensities in the green fluorescence and red fluorescence were measured to determine the levels of ERα and DNA respectively. The degradation activity with respect to estrogen receptors in this test is given by the concentration which degrades 50% of the estrogen receptor (or IC ₅₀ ) in nM. The % of ERα levels decrease were determined as follows: % inhibition = 100 * (1- (sample – fulvestrant: DMSO - fulvestrant)). The Table 2 below indicates the estrogen receptor degradation activity results for the compounds of Table 1a tested at 0.3 µM, and demonstrates that said compounds have a significant degradation activity on estrogen receptors. Table 2: It is therefore apparent that the tested compounds have degradation activities for estrogen receptors, with IC50 less than 1 µM and with degradation levels greater than 50%. The compounds of formula (I) can therefore be used for preparing medicaments, especially medicaments which are degraders of estrogen receptors. Accordingly, also provided herein are medicaments which comprise a compound of the formula (I), or a pharmaceutically acceptable salt thereof. Herein are also provided the compounds of formula (I) defined above, or pharmaceutically acceptable salts thereof, for use as medicines. Herein are also provided the compounds of formula (I) defined above, or pharmaceutically acceptable salt thereof, for use in therapy, especially as inhibitors and degraders of estrogen receptors. Herein are also provided the compounds of formula (I) defined above, or a pharmaceutically acceptable salts thereof, for use in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation. A particular aspect is a compound of formula (I) defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer. In an embodiment, the cancer is a hormone dependent cancer. In another embodiment, the cancer is an estrogen receptor dependent cancer, particularly the cancer is an estrogen receptor α dependent cancer. In another embodiment, the cancer is selected from breast, ovarian, endometrial, prostate, uterine, cervical and lung cancer, or a metastasis thereof. In another embodiment, the metastasis is a cerebral metastasis. In another embodiment, the cancer is breast cancer. Particularly, the breast cancer is an estrogen receptor positive breast cancer (ERα positive breast cancer). In another embodiment, the cancer is resistant to anti-hormonal treatment. In a further embodiment, the compound of formula (I) is as used as single agent or in combination with other agents such as CDK4/6, mTOR or PI3K inhibitors. According to another aspect, herein is provided a method of treating the pathological conditions indicated above, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In an embodiment of this method of treatment, the subject is a human. Herein is also provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful in treating any of the pathological conditions indicated above, more particularly useful in treating cancer. Herein are also provided the pharmaceutical compositions comprising as active principle a compound of formula (I). These pharmaceutical compositions comprise an effective dose of at least one compound of formula (I), or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient. The said excipients are selected, in accordance with the pharmaceutical form and method of administration desired, from the customary excipients, which are known to a person skilled in the art. In the pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intra-tracheal, intranasal, transdermal or rectal administration, the active principle of formula (I) above, or its base, acid, zwitterion or salt thereof, may be administered in a unit administration form, in a mixture with conventional pharmaceutical excipients, to animals and to human beings for the treatment of the above disorders or diseases. The unit administration forms appropriate include oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intra-tracheal, intra-ocular and intra-nasal administration forms, forms for inhalative, topical, transdermal, subcutaneous, intra-muscular or intravenous administration, rectal administration forms and implants. For topical application it is possible to use the compounds of formula (I) in creams, gels, ointments or lotions. As an example, a unit administration form of a compound of formula (I) in tablet form may comprise the following components: Compound of formula (I) 50.0 mg Mannitol 223.75 mg Sodium croscarmellose 6.0 mg Corn starch 15.0 mg Hydroxypropylmethylcellulose 2.25 mg Magnesium stearate 3.0 mg There may be particular cases in which higher or lower dosages are appropriate. According to usual practice, the dosage that is appropriate for each patient is determined by the doctor according to the mode of administration and the weight and response of the said patient.